Secure antiretroviral therapy delivery in a resource-limited setting: Streamlined to minimize drug resistance and expense

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 636-641

  Kitkungvan, D ^a   Apisarnthanarak, Anucha ^b   Laowansiri, P ^a   Mundy, L M ^c  

^a Department of Internal Medicine ^*  (Thailand)

^b THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Adherence; Annual HIV 1 RNA testing; HIV; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VIRUS RNA;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ALGORITHM; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG COSTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; PROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; THAILAND; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 52649126831     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00611.x     Document Type: Article

References (20)

1. Bagchi S, Kempf MC, Westfall AO et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44: 135-138.
2. Calmy A, Fore N, Hirschel B et al. HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin Infect Dis 2007; 44: 128-134.
3. Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005; 353: 1702-1710.
4. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://aidsinfo.nih.gov. Accessed 15 January 2007.
5. Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis 2007; 44: 139-140.
6. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl. 2): 171-176.
7. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction 2004; 99: 361-368.
8. Kresina TF, Flexner CW, Sinclair J et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18: 757-770.
9. Kiertiburanakul K, Khongnorasat S, Rattanasiri S, Sungkanuparph S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007; 90: 237-243.
10. Royal College of Physicians of Thailand. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults. 2003 Revision. http://www.rcpt.org/news. Accessed 1 February 2006.
11. World Health Organization (WHO). Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. 2003 Revision. Geneva, World Health Organization, 2003. http://www.who.int/3by5/publications/documents/arv_guideline/en. Accessed 1 February 2006.
12. Berg KM, Demas PA, Howard AA. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19: 1111-1117.
13. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43: 939-941.
14. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
15. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
16. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13: 125-131.
17. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/ AIDS Rep 2005; 2: 171-176.
18. Attaran A. Adherence to HAART: Africans take medicines more faithfully than North Americans. PLoS Med 2007; 4: E83.
19. Sungkanuparph S, Manosuthi W, Kiertiburanakul S et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-452.
20. Sungkanuparph S, Overton ET, Seyfried W et al. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41: 1326-1332.